Accelerate Diagnostics Inc (NASDAQ:AXDX) was the recipient of unusually large options trading on Monday. Traders acquired 3,074 call options on the stock. This represents an increase of 713% compared to the typical daily volume of 378 call options.
Accelerate Diagnostics (AXDX) traded up $0.35 on Wednesday, hitting $23.25. The company’s stock had a trading volume of 415,977 shares, compared to its average volume of 283,132. Accelerate Diagnostics has a 1 year low of $16.75 and a 1 year high of $30.45. The firm has a market cap of $1,290.00, a P/E ratio of -19.38 and a beta of 2.19.
In other Accelerate Diagnostics news, Director Jack W. Schuler bought 5,500 shares of Accelerate Diagnostics stock in a transaction on Friday, November 17th. The shares were purchased at an average cost of $22.00 per share, for a total transaction of $121,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 50.00% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Cpwm LLC acquired a new stake in shares of Accelerate Diagnostics in the 4th quarter valued at about $202,000. UBS Asset Management Americas Inc. acquired a new stake in shares of Accelerate Diagnostics in the fourth quarter valued at about $233,000. Teacher Retirement System of Texas acquired a new stake in shares of Accelerate Diagnostics in the fourth quarter valued at about $292,000. Intl Fcstone Inc. acquired a new stake in shares of Accelerate Diagnostics in the second quarter valued at about $322,000. Finally, Voya Investment Management LLC increased its position in shares of Accelerate Diagnostics by 13.9% in the second quarter. Voya Investment Management LLC now owns 12,193 shares of the medical research company’s stock valued at $333,000 after acquiring an additional 1,486 shares during the last quarter. 47.56% of the stock is currently owned by hedge funds and other institutional investors.
Several research analysts have weighed in on the company. Zacks Investment Research lowered Accelerate Diagnostics from a “hold” rating to a “sell” rating in a report on Monday, January 15th. BidaskClub downgraded Accelerate Diagnostics from a “buy” rating to a “hold” rating in a research note on Tuesday. ValuEngine raised Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, BTIG Research downgraded Accelerate Diagnostics from a “buy” rating to a “neutral” rating in a research note on Wednesday, December 13th. They noted that the move was a valuation call. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company. Accelerate Diagnostics currently has an average rating of “Hold” and an average price target of $33.00.
TRADEMARK VIOLATION NOTICE: “Accelerate Diagnostics Target of Unusually High Options Trading (AXDX)” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another site, it was copied illegally and reposted in violation of US & international copyright law. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/14/accelerate-diagnostics-target-of-unusually-high-options-trading-axdx.html.
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.